Research statistics
Enfuvirtide research: publications and trials
At a glance
Publications, all years
804
Since 1994
Publications in 2026 so far
1
Through November 15, 2026
Human clinical research
32.0%
252 of 787 classified
Registered clinical trials
40
ClinicalTrials.gov
Randomized controlled trials
51
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
33.4%
29 animal · 207 in vitro · 27 computational
Records that only mention it
301
Not counted above
Status in the library: FDA-approved. 17 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Enfuvirtide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1994 | 0 | 1 | 0 | 0 | 1 |
| 1995 | 0 | 1 | 0 | 1 | 2 |
| 1996 | 0 | 1 | 0 | 2 | 3 |
| 1997 | 0 | 0 | 0 | 1 | 1 |
| 1998 | 1 | 4 | 0 | 5 | 10 |
| 1999 | 0 | 2 | 2 | 9 | 13 |
| 2000 | 0 | 8 | 0 | 4 | 12 |
| 2001 | 1 | 6 | 5 | 8 | 20 |
| 2002 | 6 | 3 | 2 | 16 | 27 |
| 2003 | 12 | 9 | 19 | 43 | 83 |
| 2004 | 26 | 14 | 27 | 15 | 82 |
| 2005 | 18 | 22 | 17 | 16 | 73 |
| 2006 | 33 | 14 | 14 | 7 | 68 |
| 2007 | 31 | 17 | 6 | 9 | 63 |
| 2008 | 30 | 24 | 9 | 0 | 63 |
| 2009 | 26 | 16 | 6 | 5 | 53 |
| 2010 | 19 | 11 | 5 | 0 | 35 |
| 2011 | 16 | 15 | 4 | 2 | 37 |
| 2012 | 10 | 13 | 3 | 2 | 28 |
| 2013 | 7 | 10 | 6 | 1 | 24 |
| 2014 | 5 | 6 | 2 | 1 | 14 |
| 2015 | 3 | 8 | 2 | 1 | 14 |
| 2016 | 2 | 6 | 0 | 0 | 8 |
| 2017 | 0 | 10 | 1 | 0 | 11 |
| 2018 | 0 | 5 | 2 | 0 | 7 |
| 2019 | 1 | 17 | 1 | 0 | 19 |
| 2020 | 2 | 2 | 0 | 0 | 4 |
| 2021 | 0 | 3 | 1 | 1 | 5 |
| 2022 | 0 | 4 | 2 | 0 | 6 |
| 2023 | 1 | 5 | 1 | 0 | 7 |
| 2024 | 2 | 3 | 2 | 0 | 7 |
| 2025 | 0 | 2 | 1 | 0 | 3 |
| 2026 (to date) | 0 | 1 | 0 | 0 | 1 |
Study types
| In vitro study | 207 |
|---|---|
| Review | 139 |
| Editorial, letter or other | 128 |
| Observational human study | 85 |
| Case report | 60 |
| Other clinical trial | 56 |
| Randomized controlled trial | 51 |
| Animal study | 29 |
| Computational study | 27 |
| Not yet classified | 17 |
| Guideline or consensus | 4 |
| Meta-analysis | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Antimicrobial and infectious disease | 764 |
|---|---|
| Immune system | 470 |
| Reproductive and sexual health | 16 |
| Dermatology | 14 |
| Neurological and mental health | 11 |
| Gastrointestinal | 5 |
| Metabolic health | 5 |
| Oncology | 3 |
| Tissue repair | 3 |
| Cardiovascular | 2 |
| Cognitive health | 1 |
| Musculoskeletal | 1 |
Registered clinical trials
11 of 25 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 33 · Terminated: 4 · Unknown status: 2 · Withdrawn: 1
Early phase 1: 1 · Phase not applicable: 4 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 8 · Phase 2 / Phase 3: 1 · Phase 3: 8 · Phase 4: 14
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
HIV clinical trials · March 1, 2006 · Meta-analysis · cited 23 times · open access
PMID 16798623 · DOI 10.1310/2xvk-pbgl-735n-wh72 · Reviews and meta-analyses
- Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.
PloS one · May 23, 2019 · Randomized controlled trial · cited 24 times · open access
PMID 31120908 · DOI 10.1371/journal.pone.0216712 · Human clinical research
- Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.
AIDS research and therapy · April 2, 2016 · Randomized controlled trial · cited 15 times · open access
PMID 27042193 · DOI 10.1186/s12981-016-0101-3 · Human clinical research
- Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Journal of pharmaceutical sciences · October 7, 2014 · Randomized controlled trial · cited 10 times
PMID 25291974 · DOI 10.1002/jps.24174 · Human clinical research
- Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
The Journal of infectious diseases · June 24, 2013 · Randomized controlled trial · cited 33 times
PMID 23801606 · DOI 10.1093/infdis/jit280 · Human clinical research
- Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial agents and chemotherapy · November 19, 2012 · Randomized controlled trial · cited 19 times · open access
PMID 23165467 · DOI 10.1128/aac.01662-12 · Human clinical research
- Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
The Journal of antimicrobial chemotherapy · November 14, 2012 · Randomized controlled trial · cited 14 times
PMID 23152480 · DOI 10.1093/jac/dks455 · Human clinical research
- Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.
Journal of medical virology · November 1, 2012 · Randomized controlled trial · cited 6 times
PMID 22997073 · DOI 10.1002/jmv.23388 · Human clinical research
- Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
The Journal of antimicrobial chemotherapy · June 28, 2011 · Randomized controlled trial · cited 34 times
PMID 21712241 · DOI 10.1093/jac/dkr269 · Human clinical research
- The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
HIV medicine · January 1, 2011 · Randomized controlled trial · cited 17 times · open access
PMID 20497250 · DOI 10.1111/j.1468-1293.2010.00845.x · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrobial agents and chemotherapy · June 1, 2002 · Other clinical trial · cited 1,565 times · open access
PMID 12019106 · DOI 10.1128/aac.46.6.1896-1905.2002 · Human clinical research
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
Nature medicine · November 1, 1998 · Other clinical trial · cited 987 times
PMID 9809555 · DOI 10.1038/3293 · Human clinical research
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Proceedings of the National Academy of Sciences of the United States of America · October 1, 1994 · In vitro study · cited 931 times · open access
PMID 7937889 · DOI 10.1073/pnas.91.21.9770 · In vitro studies
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine · March 13, 2003 · Randomized controlled trial · cited 917 times · open access
PMID 12637625 · DOI 10.1056/nejmoa035026 · Human clinical research
- Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Journal of virology · September 1, 2000 · In vitro study · cited 743 times · open access
PMID 10954535 · DOI 10.1128/jvi.74.18.8358-8367.2000 · In vitro studies
Latest publications
- A four-amino-acid deletion in gp41 enhances HIV-1 CRF01_AE Cluster 4 pathogenicity and fusion inhibitor resistance.
Journal of virology · October 5, 2026 · In vitro study · cited 0 times · open access
PMID 42831624 · DOI 10.1128/jvi.01158-26 · In vitro studies
- Transdermal delivery of enfuvirtide using dissolving microneedles integrated with novel insertion and removal indicator.
Journal of controlled release : official journal of the Controlled Release Society · June 16, 2025 · Animal study · cited 9 times · open access
PMID 40532764 · DOI 10.1016/j.jconrel.2025.113954 · Animal studies
- Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.
Journal of virology · April 10, 2025 · Review · cited 6 times · open access
PMID 40207932 · DOI 10.1128/jvi.02289-24 · Reviews and meta-analyses
- Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide.
ACS applied materials & interfaces · March 10, 2025 · Animal study · cited 23 times · open access
PMID 40063825 · DOI 10.1021/acsami.5c00499 · Animal studies
- Investigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes.
Virology · December 3, 2024 · In vitro study · cited 0 times · open access
PMID 39642611 · DOI 10.1016/j.virol.2024.110341 · In vitro studies
- Recent report on indoles as a privileged anti-viral scaffold in drug discovery.
European journal of medicinal chemistry · November 1, 2024 · Review · cited 40 times · open access
PMID 39509946 · DOI 10.1016/j.ejmech.2024.117017 · Reviews and meta-analyses
- Enfuvirtide
July 15, 2024 · Review · cited 0 times · open access
PMID 30000878 · Reviews and meta-analyses
- Benign fibrous histiocytoma and cutaneous amyloidosis in a patient receiving enfuvirtide injections.
JAAD case reports · May 29, 2024 · Case report · cited 2 times · open access
PMID 39036613 · DOI 10.1016/j.jdcr.2024.04.047 · Human clinical research
- The Challenge of Adherence to a Complex Antiretroviral Therapy Regimen in an Individual With Multidrug-Resistant HIV.
Topics in antiviral medicine · April 1, 2024 · Case report · cited 1 times · open access
PMID 39141922 · Human clinical research
- Improving Anti-HIV activity and pharmacokinetics of enfuvirtide (T20) by modification with oligomannose.
European journal of medicinal chemistry · March 8, 2024 · Animal study · cited 3 times · open access
PMID 38479167 · DOI 10.1016/j.ejmech.2024.116299 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: DP-178; Enfuvirtida; Enfuvirtide; Fuzeon; Pentafuside
((TITLE_ABS:"DP-178" OR CHEM:"DP-178" OR TITLE_ABS:"DP178" OR CHEM:"DP178") OR (TITLE_ABS:"Enfuvirtida" OR CHEM:"Enfuvirtida") OR (TITLE_ABS:"Enfuvirtide" OR CHEM:"Enfuvirtide") OR (TITLE_ABS:"Fuzeon" OR CHEM:"Fuzeon") OR (TITLE_ABS:"Pentafuside" OR CHEM:"Pentafuside")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Enfuvirtide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/enfuvirtide